3 results about "Sphingomonas sp." patented technology

Therapeutic compounds and their use in the prevention and treatment of disease are disclosed. The compounds include one or more materials selected from algal biomass / supernatants (including both algae and bacteria), bacterial biomass, and isolated and purified compounds, as well as specific active sites or structures on those compounds. Therapeutic compounds derived from bacteria that appear to selectively alter one or more TLR pathways and the use of such compounds in the prevention and treatment of disease in both animals and humans. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed compounds and methods of treatment find particular use in treating diseases in poultry, particularly in the prevention and treatment of coccidiosis.

The application provides a strain of sphingomonas which can degrade phthalate, a bacterial combination and a composite microbial agent and application thereof, and belongs to the technical field of microorganisms. The application provides a strain of sphingomonas which can degrade phthalate, WXX-05, which can simultaneously degrade multiple phthalates. The application also provides a bacterial combination, which comprises the sphingomonas WXX-05 and a new species of rhizomucor WXX-04. The new species of rhizomucor WXX_04 strain and the sphingomonas WXX_05 strain can simultaneously degrade multiple phthalates. The bacterial combination of the application has strong adaptability to the environment, can effectively degrade multiple phthalates, and can improve the phthalate pollution remediation efficiency of soil by being applied to phthalate-polluted farmland soil.

This invention belongs to the field of gene editing technology, specifically relating to a scarless gene editing system for *Sphingomonas* and its application. The scarless gene editing system comprises a first inducing plasmid, a donor plasmid, and a second inducing plasmid. The first inducing plasmid includes the following elements: the EXO gene, the Gam gene, the Beta gene, a tetracycline resistance gene, and replicon 3233. The donor plasmid includes an exogenous DNA fragment for homologous recombination capable of amplifying upstream and downstream homologous arms of the target gene, an FRT fragment, and a chloramphenicol resistance gene. The second inducing plasmid includes the following elements: the FLP gene, a bleomycin resistance gene, and replicon 3233. Based on this scarless gene editing system, this invention knocks out the *Sphingomonas* 1535 gene, achieving an engineered strain capable of producing zeaxanthin, and further knocks out the 516 gene to increase zeaxanthin yield.